ARCHIVES

Phase III Trial Of PARP Inhibitor BSI-201 Opens For Triple-Negative Breast Cancer

This article is from The Cancer Letter archive.

Vol. 32 No. 7 | July 31, 2009

Download PDF Visit The Full Archive

Related Articles

Brothers Of Prostate Cancer Patients At Risk Of Diagnosis

August 27, 2010

FDA News: Avastin Combination Approved In Recurrent Ovarian Cancer

November 14, 2014

Sustained-Release Leuprolide Under Study In Phase III Trial.

June 30, 2000

DCT Board Okays Concepts Of Four New Grant Projects, Four Competitive Contract Delays Chlordane Study

March 9, 1984

John Mendelson Says M.D. Anderson Plans to Accelerate Role In Translational Research

May 7, 1999

NCI Eases Some Cooperative Group Concern; DeVita Considers Other CCOP- Research Base Funding Option

April 2, 1982